Combinatorial strategies employing nutraceuticals for cancer development

Annals of the New York Academy of Sciences

Volumn 1229, Issue 1, 2011, Pages 162-175

  Shukla, Yogeshwer ^a   George, Jasmine ^a  

^a CSIR INDIAN INSTITUTE OF TOXICOLOGY RESEARCH   (India)

Author keywords

Anticancer drugs; Cancer; Chemoprevention; Clinical trials; Nutraceuticals

Indexed keywords

3 INDOLEMETHANOL; ALLYL SULFIDE; APPLE EXTRACT; ATORVASTATIN; CAPSAICIN; CELECOXIB; CISPLATIN; CURCUMIN; DOXORUBICIN; EPICATECHIN; EPIGALLOCATECHIN GALLATE; GENISTEIN; GLYCOSIDE; GREEN TEA EXTRACT; HONOKIOL; INDOLE 3 ETHYL ISOTHIOCYANATE; LUTEOLIN; NUTRACEUTICAL; PHENYLETHYLISOATHIOCYANATE; PLANT EXTRACT; PLANT MEDICINAL PRODUCT; POLYPHENON E; POMEGRANATE EXTRACT; QUERCETIN 3 GLYCOSIDE; RESVERATROL; SILYBUM MARIANUM EXTRACT; SULINDAC; TAMOXIFEN; THIOCYANATE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; BROCCOLI; CABBAGE; CANCER COMBINATION CHEMOTHERAPY; CANCER PREVENTION; CARCINOGENESIS; CHEMOPROPHYLAXIS; CLINICAL TRIAL (TOPIC); COLORECTAL CANCER; GARLIC; GINGER; GRAPE; HUMAN; LUNG CANCER; MOUTH CANCER; NONHUMAN; OVARY CANCER; PEPPER; PROSTATE CANCER; SKIN CANCER; SOYBEAN; TOMATO;

ANIMALIA;

EID: 79960754967     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2011.06104.x     Document Type: Article

References (153)

1. Jemal, A. et al 2011. Global cancer statistics. CA. Cancer J. Clin. 61: 69-90.
2. Wogan, G.N. et al 2004. Environmental and chemical carcinogenesis. Semin. Cancer Biol. 14: 473-486.
3. Surh, Y.J. 2003. Cancer chemoprevention with dietary phytochemicals. Nat. Rev. Cancer 3: 768-780.
4. de Kok, T.M., S.G. van Breda & M.M. Manson 2008. Mechanisms of combined action of different chemopreventive dietary compounds: a review. Eur. J. Nutr. 2: 51-59.
5. Brower, V. 1998. Nutraceuticals: poised for a healthy slice of the healthcare market Nat. Biotechnol. 16: 728-731.
6. Zeisel, S.H. 1999. Regulation of "nutraceuticals. Science 285: 185-186.
7. Camire, M.E. 2003. Nutraceuticals for health promotion and disease prevention. Council for Agricultural and Technology, Issue paper no. 24.
8. Amin, A.R. et al 2009. Perspectives for cancer prevention with natural compounds. J. Clin Oncol. 27: 2712-2725.
9. Martinez, M.E., J.R. Marshall & E. Giovannucci 2008. Diet and cancer prevention: the roles of observation and experimentation. Nature Rev. Cancer 8: 694-703.
10. Aggarwal, B.B. & P. Gehlot 2009. Inflammation and cancer: how friendly is the relationship for cancer patients Curr. Opin. Pharmacol. 9: 351-369.
11. Philip, M. et al 2004. Inflammation as a tumor promoter in cancer induction. Semin. Cancer Biol. 14: 433-439.
12. Li, Q., S. Withoff & I.M. Verma 2005. Inflammation-associated cancer: NF-kB is the lynchpin. Trends Immunol. 26: 318-325.
13. Marx, J. 2004. Cancer research. Inflammation and cancer: the link grows stronger. Science 306: 966-968.
14. Karin, M. & F.R. Greten 2005. NF-κB: linking inflammation and immunity to cancer development and progression. Nature Rev. Immunol 5: 749-759.
15. Karin M. 2009. NF-kappaB as a critical link between inflammation and cancer. Cold Spring Harb. Perspect. Biol. 1: a000141.
16. Shishodia, S. & B.B. Aggarwal 2004. Guggulsterone inhibits NF-kappaB and IkappaBalpha kinase activation, suppresses expression of anti-apoptotic gene products, and enhances apoptosis. J. Biol. Chem. 279: 47148-47158.
17. Siddiqui, I.A. et al 2008. Suppression of NFkappaB and its regulated gene products by oral administration of green tea polyphenols in an autochthonous mouse prostate cancer model. Pharm. Res. 25: 2135-2142.
18. Bhui, K. et al 2009. Bromelain inhibits COX-2 expression by blocking the activation of MAPK regulated NF-kappa B against skin tumor-initiation triggering mitochondrial death pathway. Cancer Lett. 282: 167-176.
19. Roy, P. et al 2009. Resveratrol enhances ultraviolet B-induced cell death through nuclear factor-kappaB pathway in human epidermoid carcinoma A431 cells. Biochem. Biophys. Res. Comm. 384: 215-220.
20. Galli, F. et al 2005. Oxidative stress and reactive oxygen species. Contrib. Nephrol. 149: 240-260.
21. Ames, B.N., M.K. Shigenaga & L.S. Gold 1993. DNA lesions, inducible DNA repair, and cell division: the three key factors in mutagenesis and carcinogenesis. Environ. Health Perspect. 101(Suppl 5): 35-44.
22. Thannickal, V.J. & B.L. Fanburg 2000. Reactive oxygen species in cell signaling. Am. J. Physiol. Lung Cell Mol. Physiol. 279: L1005-L1028.
23. Chu, Y-F. et al 2002. Antioxidant and antiproliferative activities of vegetables. J. Agric. Food Chem. 50: 6910-6916.
24. Dragsted, L.O., M. Strube & J.C. Larsen 1993. Cancer-protective factors in fruits and vegetables: biochemical and biological background. Pharmacol. Toxicol. 72: 116-135.
25. Liu, R.H. & D.L. Felice 2007. Antioxidants and whole food phytochemicals for cancer prevention. Antioxidant measurement and mechanism. ACS Symposium Series Vol. 956, Chapter 3, pp 15-34.
26. Green, D.R. 2000. Apoptotic pathways: paper wraps stone blunts scissors. Cell 102: 1-4.
27. Meier, P., A. Finch & G. Evan 2000. Apoptosis in development. Nature 407: 796-801.
28. Hanahan, D., & R.A. Weinberg 2000. The hallmarks of cancer. Cell 100: 57-70.
29. Wang, S., D. Yang & M.E. Lippman 2003. Targeting Bcl-2 and Bcl-XL with nonpeptidic small-molecule antagonists. Semin. Oncol. 30: 133-142.
30. Gosslau, A., & K.Y. Chen 2004. Nutraceuticals, apoptosis, and disease prevention. Nutrition 1: 95-102.
31. Liu, R.H. 2004. Potential synergy of phytochemicals in cancer prevention: mechanism of action. J. Nutr. 134(12 Suppl): 3479S-3485S.
32. Jemal, A. et al 2010. Cancer statistics. CA Cancer J. Clin. 60: 277-300.
33. Schmid, H.P., J.E. McNeal & T.A. Stamey 1993. Observations on the doubling time of prostate cancer. The use of serial prostate-specific antigen in patients with untreated disease as a measure of increasing cancer volume. Cancer 71: 2031-2040.
34. Ries, L. et al 2004. SEER Cancer Statistics Review, 1975-2004. National Cancer Institute. Bethesda, MD.
35. Zhang, Y. 2004. Cancer-preventive isothiocyanates: measurement of human exposure and mechanism of action. Mutat. Res. 555: 173-190.
36. Singh, A.V. et al 2004. Sulforaphane induces caspase-mediated apoptosis in cultured PC-3 human prostate cancer cells and retards growth of PC-3 xenografts in vivo. Carcinogenesis 25: 83-90.
37. Xiao, D. et al 2005. Caspase-dependent apoptosis induction by phenethyl isothiocyanate, a cruciferous vegetable-derived cancer chemopreventive agent, is mediated by Bak and Bax. Clin. Cancer Res. 11: 2670-2679.
38. Rushmore, T.H. & A.N. Kong 2002. Pharmacogenomics, regulation and signaling pathways of phase I and II drug metabolizing enzymes. Curr. Drug Metab. 3: 481-490.
39. Sharma, O.P. 1976. Antioxidant activity of curcumin and related compounds. Biochem. Pharmacol. 25: 1811-1812.
40. Chaudhary, L.R. & K.A. Hruska 2003. Inhibition of cell survival signal protein kinase B/Akt by curcumin in human prostate cancer cells. J. Cell. Biochem. 89: 1-5.
41. Huang, M.T. et al 1988. Inhibitory effect of curcumin, chlorogenic acid, caffeic acid, and ferulic acid on tumor promotion in mouse skin by 12-O-tetradecanoylphorbol-13-acetate. Cancer Res. 48: 5941-596.
42. Huang, M.T. et al 1992. Inhibitory effects of curcumin on tumor initiation by benzo[a]pyrene and 7, 12-dimethylbenz4 [a]anthracene. Carcinogenesis. 13: 2183-2186.
43. Huang, M.T. et al 1994. Inhibitory effects of dietary curcumin on forestomach, duodenal, and colon carcinogenesis in mice. Cancer Res. 54: 5841-5847.
44. Kim, J.H. et al 2006. Inhibition of EGFR signaling in human prostate cancer PC-3 cells by combination treatment with beta-phenylethyl isothiocyanate and curcumin. Carcinogenesis 27: 475-482.
45. Khor, T.O. et al 2006. Combined inhibitory effects of curcumin and phenethyl isothiocyanate on the growth of human PC-3 prostate xenografts in immunodeficient mice. Cancer Res. 66: 613-621.
46. Ravindranath, M.H. et al 2004. Anticancer therapeutic potential of soy isoflavone, genistein. Adv. Exp. Med. Biol. 546: 121-165.
47. De Lemos, M.L. 2001. Effects of soy phytoestrogens genistein and daidzein on breast cancer growth. Ann. Pharmacother. 35: 1118-1121.
48. Mccue, P. & K. Shetty 2004. Health benefits of soy isoflavonoids and strategies for enhancement: a review. Crit. Rev. Food Sci. Nutr. 44: 361-367.
49. Zhou, J.R. et al 1999. Soybean phytochemicals inhibit the growth of transplantable human prostate carcinoma and tumor angiogenesis in mice. J. Nutr. 19: 1628-1635.
50. Banerjee, S., C. Bueso-Ramos & B.B. Aggarwal 2002. Suppression of 7, 12- dimethylbenz(a)anthracene-induced mammary carcinogenesis in rats by resveratrol: role of nuclear factor-kappaB, cyclooxygenase 2, and matrix metalloprotease 9. Cancer Res. 17: 4945-4954.
51. Bhat, K.P. et al 2001. Estrogenic and antiestrogenic properties of resveratrol in mammary tumor models. Cancer Res. 20: 7456-7463.
52. Whitsett, T.M., Carpenter & C.A. Lamartiniere 2006. Resveratrol, but not EGCG, in the diet suppresses DMBA-induced mammary cancer in rats. J. Carcinog. 5: 15-25.
53. Harper, C.E. et al 2009. Genistein and resveratrol, alone and in combination, suppress prostate cancer in SV-40 tag rats. Prostate 15: 1668-1682.
54. Klein, R.D. & S.M. Fischer 2002. Black tea polyphenols inhibit IGF-I-induced signaling through Akt in normal prostate epithelial cells and Du145 prostate carcinoma cells. Carcinogenesis 23: 217-221.
55. Zhou, J.R. et al 2003. Soy phytochemicals and tea bioactive components synergistically inhibit androgen-sensitive human prostate tumors in mice. J. Nutr. 133: 516-521.
56. Hsieh, T. & M.J. Wu 2009. Targeting cwr22rv1 prostate cancer cell proliferation and gene expression by combinations of the phytochemicals egcg, genistein and quercetin. Anticancer Res. 29: 4025-4032.
57. Forbes, J.F. 1997. The control of breast cancer: the role of tamoxifen. Semin. Oncol. 24: 15-19.
58. Boyer, J. & R.H. Liu 2004. Apple phytochemicals and their health benefits. Nutr. J. 3: 1-45.
59. Yang, J. & R.H. Liu 2009. Synergistic effect of apple extracts and quercetin 3-β-d-glucoside combination on antiproliferative activity in MCF-7 human breast cancer cells in vitro. J. Agric. Food Chem. 57: 8581-8586.
60. Kousidou, O., G.N. Tzanakakis & N.K. Karamanos 2006. Effects of the natural isoflavonoid genistein on growth, signaling pathways and gene expression of matrix macromolecules by breast cancer cells. Mini Rev. Med. Chem. 6: 331-337.
61. Hwang, J.T. et al 2009. Anti-inflammatory and anticarcinogenic effect of genistein alone or in combination with capsaicin in TPA-treated rat mammary glands or mammary cancer cell line. Ann. N. Y. Acad. Sci. 1171: 415-420.
62. World Health Organization (WHO), 2009. Cancer Fact sheet n 297.
63. Pisani, P., F. Bray & D.M. Parkin 2002. Estimates of the world-wide prevalence of cancer for 25 sites in the adult population. Int. J. Cancer 97: 72-81.
64. Aggarwal, B.B., A. Kumar & Bharti A.C. 2003. Anticancer potential of curcumin: preclinical and clinical studies. Anticancer Res. 23: 363-398.
65. Johnson, J.J. & H. Mukhtar 2007. Curcumin for chemoprevention of colon cancer. Cancer Lett. 255: 170-181.
66. Anand, P. et al 2008. Curcumin and cancer: an ''old-age" disease with an ''age-old" solution. Cancer Lett. 267: 133-164.
67. Yang, C.S. & Z.Y. Wang 1993. Tea and cancer. J. Natl. Cancer Inst. 85: 1038-1049.
68. Stoner, G.D. & H. Mukhtar 1995. Polyphenols as cancer chemopreventive agents. J. Cell Biochem. 22(Suppl.): 169-180.
69. Ji, B.T. et al 1997. Green tea consumption and the risk of pancreatic and colorectal cancers. Int. J. Cancer 70: 255-258.
70. Yang, C.S., P. Maliakal & X. Meng 2002. Inhibition of carcinogenesis by tea. Annu. Rev. Pharmacol. Toxicol. 42: 25-54.
71. Ahmad, N. et al 1997. Green tea constituent epigallocatechin-3- gallate and induction of apoptosis and cell cycle arrest in human carcinoma cells. J. Natl. Cancer Inst. 89: 1881-1886.
72. Yang, G.Y. et al 1998. Inhibition of growth and induction of apoptosis in human cancer cell lines by tea polyphenols. Carcinogenesis 19: 611-616.
73. Xu, G. et al 2010. Combination of curcumin and green tea catechins prevents dimethylhydrazine-induced colon carcinogenesis. Food Chem. Toxicol. 1: 390-395.
74. Ohishi, T. et al 2002. Synergistic effects of (-)-epigallocatechin gallate with sulindac against colon carcinogenesis of rats treated with azoxymethane. Cancer Lett. 177: 49-56.
75. Shimizu, M. et al 2005. (-)-Epigallocatechin gallate and polyphenon E inhibit growth and activation of the epidermal growth factor receptor and human epidermal growth factor receptor-2 signaling pathways in human colon cancer cells. Clin. Cancer Res. 7: 2735-2746.
76. Kim, N.D. et al 2002. Chemoprevetive and adjuvant therapeutic potential of pomegranate (Punica granatum) for human breast cancer. Breast Cancer Res. Treat. 71: 203-217.
77. Pantuck, A.J. et al 2006. Phase-II study of pomegranate juice for men with rising prostate-specific antigen following surgery or radiation for prostate cance. Clin. Cancer Res. 12: 4018-4026.
78. Afaq, F. et al 2005. Anthocyanin- and hydrolysable tannin-rich pomegranate fruit extract modulates MAPK and NF-KB pathways and inhibits skin tumorigenesis in CD-1 mice. Int. J. Cancer 113: 423-433.
79. Fleischauer, A.T., C. Poole & L. Arab 2000. Garlic consumption and cancer prevention: meta-analyses of colorectal and stomach cancers. Am. J. Clin. Nutr. 72: 1047-1052.
80. Gil, M.I. et al 2000. Antioxidant activity of pomegranate juice and its relationship with phenolic composition and processing. J. Agric. Food Chem. 48: 4581-4589.
81. Kaur, G. et al 2006. Punica granatum (pomegranate) flower extract possesses potent antioxidant activity and abrogates Fe- NTA induced hepatotoxicity in mice. Food Chem. Toxicol. 44: 984-993.
82. Seeram, N.P. et al 2005. In vitro antiproliferative, apoptotic and antioxidant activities of punicalagin, ellagic acid and a total pomegranate tannin extract are enhanced in combination with other polyphenols as found in pomegranate juice. J. Nutr. Biochem. 16: 360-367.
83. Adams, L.S. et al 2006. Pomegranate juice, total pomegranate ellagitannins, and punicalagin suppress inflammatory cell signaling in colon cancer cells. J. Agric. Food Chem. 54: 980-985.
84. Malik, A. et al 2005. Pomegranate fruit juice for chemoprevention and chemotherapy of prostate cancer. Proc. Natl. Acad. Sci. USA 102: 14813-14818.
85. Dausch, J.G. & D.W. Nixon 1990. Garlic: a review of its relationship to malignant disease. Prev. Med. 19: 346-361.
86. George, J. et al 2011. Synergistic growth inhibition of mouse skin tumors by pomegranate fruit extract and diallyl sulfide: evidence for inhibition of activated MAPKs/NF-κB and reduced cell proliferation. Food Chem. Toxicol. 49: 1511-1520.
87. Miean, K.H. & S. Mohamed 2001. Flavonoid (myricetin, quercetin, kaempferol, luteolin, and apigenin) content of edible tropical plants. J. Agric. Food. Chem. 49: 3106-3112.
88. Shimoi, K. et al 2000. Metabolic fate of luteolin and its functional activity at focal site. Biofactors 12: 181-186.
89. Amin, A.R. et al 2010. Enhanced anti-tumor activity by the combination of the natural compounds (-)-epigallocatechin-3-gallate and luteolin: potential role of p53. J. Biol. Chem. 45: 34557-34565.
90. Kassie, F. et al. (2010. Inhibition of lung carcinogenesis and critical cancer-related signaling pathways by N-acetyl-S-(N-2-phenethylthiocarbamoyl)-l-cysteine, indole-3-carbinol and myo-inositol, alone and in combination. Carcinogenesis 9: 1634-1641.
91. Sankaranarayanan, R. 1990. Oral caner in India: an epidemiologic and clinical review. Oral Sirg. Oral Med. Oral Path. 69: 325-330.
92. Silverman, S. Jr., M. Gorsky & F. Lozada 1984. Oral leukoplakia and malignant transformation. A follow-up study of 257 patients. Cancer 3: 563-568.
93. Morse, D.E. et al 2000. Food group intake and the risk of oral epithelial dysplasia in a United States population. Cancer Causes Control 8: 713-720.
94. La Vecchia, C. et al 1997. Epidemiology and prevention of oral cancer. Oral Oncol. 5: 302-312.
95. Giovannucci, E. 1999. Tomatoes, tomato-based products, lycopene, and cancer: review of the epidemiologic literature. J. Natl. Cancer Inst. 91: 317-331.
96. Thomson, M. & M. Ali 2003. Garlic (Allium sativum): a review of its potential use as an anti-cancer agent. Curr. Cancer Drug Targets 3: 67-81.
97. Yang, C.M. et al 2011. Lycopene inhibits the proliferation of androgen-dependent human prostate tumor cells through activation of PPARγ-LXRα-ABCA1 pathway. J. Nutr. Biochem. 3: 67-81.
98. Lu, R. et al 2011. Lycopene: features and potential significance in the oral cancer and precancerous lesions. J. Oral Pathol. Med. 5: 361-368.
99. Bhuvaneswari, V. et al 2004. Tomato and garlic by gavage modulate 7, 12-dimethylbenz[a]anthracene-induced genotoxicity and oxidative stress in mice. Braz. J. Med. Biol. Res. 7: 1029-1034.
100. Bhuvaneswari, V., S.K. Abraham & S. Nagini 2005. Combinatorial antigenotoxic and anticarcinogenic effects of tomato and garlic through modulation of xenobiotic-metabolizing enzymes during hamster buccal pouch carcinogenesis. Nutrition 6: 726-731.
101. Khafif, A. et al 1998. Quantitation of chemopreventive synergism between (-)-epigallocatechin-3-gallate and curcumin in normal, premalignant and malignant human oral epithelial cells. Carcinogenesis 3: 419-424.
102. Li, N. et al 2002. Inhibition of 7, 12-dimethylbenz[a]anthracene (DMBA)- induced oral carcinogenesis in hamsters by tea and curcumin. Carcinogenesis 23: 1307-1313.
103. Chinni, S.R. et al 2001. Indole-3-Carbinol induced cell growth inhibition, G1 cell cycle arrest and apoptosis in prostate cancer cells. Oncogene 20: 2927-2936.
104. Kim, D.S. et al 2006. Indole-3-carbinol enhances ultraviolet B-induced apoptosis by sensitizing melanoma cells. Cell. Mol. Life. Sci. 63: 2661-2668.
105. Kim, Y.S. & J.A. Milner 2005. Targets for indole-3-carbinol in cancer prevention. J. Nutr. Biochem. 16: 65-73.
106. Weng, J.R. et al 2008. Indole-3-carbinol as a chemopreventive and anti-cancer agent. Cancer Lett. 262: 153-163.
107. Raj, M.H. et al 2008. Synergistic action of dietary phyto-antioxidants on survival and proliferation of ovarian cancer cells. Gynecol. Oncol. 3: 432-438.
108. Suganuma, M., A. Saha & H. Fujiki 2011. New cancer treatment strategy using combination of green tea catechins and anticancer drugs. Cancer Sci. 2: 317-323.
109. Qiu M, C. Yi & M. Hou 2006. Combined low-dose chemotherapy inhibiting angiogenesis and growth of Lewis lung carcinoma xenografts in mice. J. Sichuan. Univ. 37: 534-537.
110. Konoshima, T. et al 1991. Studies on inhibitors of skin tumor promotion, IX: neolignans fromMagnolia officinalis. J. Nat. Prod. 54: 816-822.
111. Wang, T. et al 2004. Honokiol induces apoptosis through p53-independent pathway in human colorectal cell line RKO. World J. Gastroenterol. 10: 2205-2208.
112. Feleszko, W. et al 2002. Lovastatin potentiates antitumor activity of doxorubicin in murine melanoma via an apoptosis-dependent mechanism. Int. J. Cancer 100: 111-118.
113. Safrit, J.T. & B. Bonavida 1992. Sensitivity of resistant human tumor cell lines to tumor necrosis factor and adriamycin used in combination: correlation between down-regulation of tumor necrosis factor-messenger RNA induction and overcoming resistance. Cancer Res. 52: 6630-6637.
114. Cutts, S.M. et al 1996. Adriamycininduced DNA adducts inhibit the DNA interactions of transcription factors and RNA polymerase. J. Biol. Chem. 271: 5422-5429.
115. Tanaka, M. & S. Yoshisa 1980. Mechanism of the inhibition of calf thymus DNA polymerase α and β by daunomycin and adriamycin. J. Biochem. 87: 911-918.
116. Tewey, K.M. et al 1984. Adriamycin-induced DNA damage mediated by mammalian DNA topoisomerase II. Science 226: 466-468.
117. Zhu, K. et al 1999. Adriamycin inhibits human RH II/Gu RNA helicase activity by binding to its substrate. Biochem. Biophys. Res. Commun. 266: 361-365.
118. Hou W, et al 2008. Synergistic antitumor effects of liposomal Honokiol combined with Adriamycin in breast cancer models. Phytother. Res. 22: 1125-1132.
119. Buchwald, H. 1992. Cholesterol inhibition, cancer, and chemotherapy. Lancet 339: 1154-1156.
120. Larsson, O. 1996. HMG-CoA reductase inhibitors: role in normal and malignant cells. Crit. Rev. Oncol. Hematol. 22: 197-212.
121. Lu, G. et al 2008. Synergistic inhibition of lung tumorigenesis by a combination of green tea polyphenols and atorvastatin. Clin. Cancer Res. 15: 4981-4988.
122. Masuda, M.M. Suzui & I.B. Weinstein 2001. Effects of epigallocatechin-3-gallate of growth, epidermal growth factor receptor signaling pathways, gene expression, and chemosensitivity in human head and neck squamous cell carcinoma cell lines. Clin. Cancer Res. 7: 4220-4229.
123. Masuda, M. et al 2003. Epigallocatechin-3-gallate inhibits activation of HER-2/neu and downstream signaling pathways in human head and neck and breast carcinoma cells. Clin. Cancer Res. 9: 3486-3491.
124. Liang, G. et al 2010. Green tea catechins augment the antitumor activity of doxorubicin in an in vivo mouse model for chemoresistant liver cancer. Int. J. Oncol. 37: 111-123.
125. Stuart, E.C., L. Larsen & R.J. Rosengren 2007. Potential mechanisms for the synergistic cytotoxicity elicited by 4-hydroxytamoxifen and epigallocatechin gallate in MDA-MB-231cells. Int. J. Oncol. 30: 1407-1412.
126. Sartippour, M.R. et al 2006. The combination of green tea and tamoxifen is effective against breast cancer. Carcinogenesis 27: 2424-2433.
127. Flora, K. et al 1998. Milk thistle (Silybum marianum) for the therapy of liver disease. Am. J. Gastroenterol. 93: 139-143.
128. Wagner, H., L. Horhammer & M. Seitz 1968. [Chemical evaluation of a silymarin-containing flavonoid concentrates from Silybum marianum (L.) Gaertn]. Arzneimittelforschung 18: 696-698.
129. Zhu, W., J.S. Zhang & C.Y. Young 2001. Young Silymarin inhibits function of the androgen receptor by reducing nuclear localization of the receptor in the human prostate cancer cell line LNCaP. Carcinogenesis 22: 1399-1403.
130. Tyagi, A. et al 2004. Silibinin causes cell cycle arrest and apoptosis in human bladder transitional cell carcinoma cells by regulating CDKI-CDK-cyclin cascade, and caspase 3 and PARP cleavages. Carcinogenesis 25: 1711-1720.
131. Yang, S.H. et al 2003. Anti-angiogenic effect of silymarin on colon cancer LoVo cell line. J. Surg. Res. 113: 133-138.
132. Singh, R.P. et al 2002. Dietary feeding of silibinin inhibits advance human prostate carcinoma growth in athymic nude mice and increases plasma insulin-like growth factor-binding protein-3 levels. Cancer Res. 62: 3063-3069.
133. Lahiri-Chatterjee, M. et al 1999. A flavonoid antioxidant, silymarin, affords exceptionally high protection against tumor promotion in the SENCAR mouse skin tumorigenesis model. Cancer Res. 59: 622-632.
134. Zi, X., D.K. Feyes & R. Agarwal 1998. Anticarcinogenic effect of a flavonoid antioxidant, silymarin, in human breast cancer cells MDA-MB 468: induction of G1 arrest through an increase in Cip1/p21 concomitant with a decrease in kinase activity of cyclin-dependent kinases and associated cyclins. Clin. Cancer Res. 4: 1055-1064.
135. Singh R.P. & R. Agarwal 2004. Prostate cancer prevention by silibinin. Curr. Cancer Drug Targets 4: 1-11.
136. Zi, X. & R. Agarwal 1999. Silibinin decreases prostate-specific antigen with cell growth inhibition via G1 arrest, leading to differentiation of prostate carcinoma cells: implications for prostate cancer intervention. Proc. Natl. Acad. Sci. USA 96: 7490-7495.
137. Tyagi, A., C. Agarwal & R. Agarwal 2002. Inhibition of retinoblastoma protein (Rb) phosphorylation at serine sites and an increase in Rb-E2F complex formation by silibinin in androgen-dependent human prostate carcinoma LNCaP cells: role in prostate cancer prevention. Mol. Cancer Ther. 1: 525-532.
138. Tyagi, A.K. et al 2002. Silibinin strongly synergizes human prostate carcinoma DU145 cells to doxorubicin- induced growth inhibition, G2-M arrest, and apoptosis. Clin. Cancer Res. 8: 3512-3519.
139. Dhanalakshmi, S. et al 2003. Silibinin sensitizes human prostate carcinoma DU145 cells to cisplatin- and carboplatin- induced growth inhibition and apoptotic death. Int. J. Cancer 106: 699-705.
140. Flaig, T.W. et al 2007. Silibinin synergizes with mitoxantrone to inhibit cell growth and induce apoptosis in human prostate cancer cells. Int. J. Cancer 19: 2028-2033.
141. Shpitz, B. et al 2006. Celecoxib and curcumin additively inhibit the growth of colorectal cancer in a rat model. Digestion 74: 140-144.
142. Kunnumakkara, A.B. et al 2007. Curcumin potentiates antitumor activity of gemcitabine in an orthotopic model of pancreatic cancer through suppression of proliferation, angiogenesis, and inhibition of nuclear factor kappa B- regulated gene products. Cancer Res. 67: 3853-3861.
143. Lev-Ari, S. et al 2005. Curcumin synergistically potentiates the growth inhibitory and pro-apoptotic effects of celecoxib in pancreatic adenocarcinoma cells. Biomed. Pharmacother. 59(Suppl. 2): S276-S280.
144. Stehlik, P., H. Paulikova & L. Hunakova 2010. Synthetic isothiocyanate indole-3-ethyl isothiocyanate (homoITC) enhances sensitivity of human ovarian carcinoma cell lines A2780 and A2780/CP to cisplatin. Neoplasma 5: 473-481.
145. Crispen, P.L. et al 2007. Vitamin E succinate inhibits NF-kappaB and prevents the development of a metastatic phenotype in prostate cancer cells: implications for chemoprevention. Prostate 67: 582-590.
146. Ip, C. et al 2000. In vitro and in vivo studies of methylseleninic acid: evidence that a monomethylated selenium metabolite is critical for cancer chemoprevention. Cancer Res. 60: 2882-2886.
147. Venkateswaran, V., N.E. Fleshner & L.H. Klotz 2004. Synergistic effect of vitamin E and selenium in human prostate cancer cell lines. Prostate Cancer Prostatic Dis. 7: 54-56.
148. Morris, V.C. & O.A. Levander 1970. Selenium content of foods. J. Nutr. 100: 1383-1388.
149. Schrauzer, G.N. 2001. Nutritional selenium supplements: product types, quality, and safety. J. Am. Coll. Nutr. 20: 1-4.
150. Harris, P.L., M.L. Quaife & W.J. Swanson 1950. Vitamin E content of foods. J. Nutr. 40: 367-381.
151. Lippman, S.M. et al 2009. Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA 301: 39-51.
152. McCormick, D.L. et al 2010. Null activity of selenium and vitamin e as cancer chemopreventive agents in the rat prostate. Cancer Prev. Res (Phila). 3: 381-392.
153. Vidlar, A. et al 2010. The safety and efficacy of a silymarin and selenium combination in men after radical prostatectomy: a six month placebo-controlled double-blind clinical trial. Biomed. Pap. Med. Fac. Univ. Palacky. Olomouc. Czech. Repub. 3: 239-244.